CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionReturn on equity is -167.7%, lower than 95% of its Biotechnology peers (median -22.3%)
- FinancialsAltman Z-Score -1.39: distress zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
957.22MUSDvs all stocks (USD)
Revenue (TTM)
77.22MUSDvs all stocks (USD)
Beta
0.4340xvs all stocks
52-Week Change
19.96%vs all stocks
Market Capitalization
957.22MUSDvs all stocks (USD)
Enterprise Value
462.65MUSDvs all stocks (USD)
Forward P/E
-4.69xvs Biotechnology peers
Price to Sales (TTM)
12.40xvs Biotechnology peers
Price to Book (MRQ)
19.78xvs Biotechnology peers
Enterprise to Revenue
5.99xvs Biotechnology peers
Enterprise to EBITDA
-1.46xvs Biotechnology peers
Gross Margin
98.84%vs Biotechnology peers
Operating Margin
-349.77%vs Biotechnology peers
Return on Assets (TTM)
-31.30%vs Biotechnology peers
Return on Equity (TTM)
-167.71%vs Biotechnology peers
Revenue (TTM)
77.22MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.8750USDUpdated Sep 27, 2026Quarterly Revenue Growth
36.50%vs Biotechnology peers
Gross Profit (TTM)
-182.81MUSDvs all stocks (USD)
EBITDA (TTM)
-316.80MUSDvs all stocks (USD)
Net Income (TTM)
-296.78MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
36.54%vs Biotechnology peers
Operating Cash Flow (TTM)
-111.76MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-165.88MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
67.48MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
57.00KUSDFY2025 · Dec 31, 2025Gross Profit
67.42MUSDFY2025 · Dec 31, 2025Operating Income
-303.63MUSDvs all stocks (USD)
Pre-tax Income
-278.37MUSDFY2025 · Dec 31, 2025Income Tax Expense
297.00KUSDFY2025 · Dec 31, 2025Net Income
-278.67MUSDFY2025 · Dec 31, 2025EBIT
-276.86MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-275.82MUSDFY2025 · Dec 31, 2025Research & Development
251.07MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
119.98MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
26.77MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
1.51MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.18USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.18USDFY2025 · Dec 31, 2025Basic Shares Outstanding
87.68MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
87.68MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-278.67MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-52.27MUSDFY2025 · Dec 31, 2025Free Cash Flow
-58.91MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
149.10MUSDFY2025 · Dec 31, 2025Interest Paid
998.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-278.67MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.03MUSDFY2025 · Dec 31, 2025Stock-based Compensation
37.11MUSDFY2025 · Dec 31, 2025Other Non-cash Items
515.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-6.74MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
4.50MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
189.98MUSDFY2025 · Dec 31, 2025Capital Expenditures
-6.64MUSDFY2025 · Dec 31, 2025Purchase of Investments
-761.59MUSDFY2025 · Dec 31, 2025Sale of Investments
755.13MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-13.10MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
88.95MSharesUpdated Sep 27, 2026Float Shares
70.44MSharesUpdated Sep 27, 2026Shares Short
14.82MSharesUpdated Sep 27, 2026Short Ratio
6.42daysvs all stocks
Short % of Shares Outstanding
17.10%vs all stocks
% Held by Insiders
1.39%vs all stocks
% Held by Institutions
99.77%vs all stocks
Total Cash (MRQ)
519.02MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.83USDUpdated Sep 27, 2026Total Debt (MRQ)
24.45MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.5050xvs Biotechnology peers
Current Ratio (MRQ)
4.73xvs Biotechnology peers
Book Value per Share (MRQ)
0.5440USDUpdated Sep 27, 2026Total Assets
738.36MUSDvs all stocks (USD)
Total Current Assets
708.66MUSDFY2025 · Dec 31, 2025Total Liabilities
564.23MUSDFY2025 · Dec 31, 2025Total Non-current Assets
29.70MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
447.25MUSDFY2025 · Dec 31, 2025Total Current Liabilities
116.97MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
149.10MUSDFY2025 · Dec 31, 2025Other Short-term Investments
518.14MUSDFY2025 · Dec 31, 2025Accounts Receivable
8.80MUSDFY2025 · Dec 31, 2025Inventory
413.00KUSDFY2025 · Dec 31, 2025Accounts Payable
5.02MUSDFY2025 · Dec 31, 2025Short-term Debt
1.28MUSDFY2025 · Dec 31, 2025Deferred Revenue
48.98MUSDFY2025 · Dec 31, 2025Long-term Debt
19.18MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
3.17MUSDFY2025 · Dec 31, 2025Common Stock (Book)
9.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.17BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
174.13MUSDvs all stocks (USD)
52-Week Low
7.36USDUpdated Sep 27, 202652-Week High
13.90USDUpdated Sep 27, 202652-Week Change
19.96%vs all stocks
Beta
0.4340xvs all stocks
50-Day MA
11.17USDUpdated Sep 27, 2026200-Day MA
9.80USDUpdated Sep 27, 2026Avg 10-Day Volume
1.88MSharesUpdated Sep 27, 2026Avg 30-Day Volume
2.20MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-3.32USDUpdated Sep 27, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -167.7%, lower than 95% of its Biotechnology peers (median -22.3%)Significant
Return on equity: -1.68Industry median: -0.22Industry P5: -1.57Peers compared: 260
Price-to-book is 19.78×, higher than 95% of its Biotechnology peers (median 2.86×)Significant
Price-to-book: 19.78Industry median: 2.86Industry P95: 13.08Peers compared: 260
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 4.73Altman Z-Score: -1.39
Financial Health
Altman Z-Score -1.39: distress zoneCritical
Altman Z-Score: -1.39
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Green Cross Corporation
Tier 1ProductionApproval-Gated PipelineRule
Arbutus Biopharma Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hangzhou Biotest Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cullinan Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pharma Resources Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Tong Ren Tang Chinese Medicine Company Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Suven Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Bioventus Inc.
Tier 1ProductionApproval-Gated PipelineRule
Suzhou Highfine Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
KPC Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Assembly Biosciences Inc.
2 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Indie Semiconductor, Inc.
2 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
IonQ, Inc.
2 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated